The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Relationship between tumor burden to growth rate and treatment outcomes of nivolumab for patients with head and neck squamous carcinoma.
 
Chiaki Suzuki
No Relationships to Disclose
 
Naomi Kiyota
Honoraria - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Eisai; Merck Serono; Ono Pharmaceutical
Speakers' Bureau - AstraZeneca; Bayer; Bristol-Myers Squibb Japan; Eisai; Merck Serono; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst)
 
Yoshinori Imamura
No Relationships to Disclose
 
Junpei Rikitake
No Relationships to Disclose
 
Satoshi Sai
No Relationships to Disclose
 
Taiji Koyama
No Relationships to Disclose
 
Yasuko Hyogo
No Relationships to Disclose
 
Yoshiaki Nagatani
No Relationships to Disclose
 
Yohei Funakoshi
No Relationships to Disclose
 
Masanori Toyoda
No Relationships to Disclose
 
Naoki Otsuki
No Relationships to Disclose
 
Ken-ichi Nibu
No Relationships to Disclose
 
Hironobu Minami
Honoraria - Bayer; Bristol-Myers Squibb Japan; Celgene; Chugai Pharma; Daiichi Sankyo; Dainippon Sumitomo Pharma; Eisai; Janssen; Kowa; Kyowa Hakko Kirin; Lilly Japan; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Otsuka; Pfizer; Sanofi; Shire; Taiho Pharmaceutical; Takeda
Consulting or Advisory Role - Merck Serono; Ono Pharmaceutical
Research Funding - Asahi Kasei (Inst); Astellas Pharma (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); CSL Behring (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); MSD (Inst); Nippon Shinyaku (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); Yakult Honsha (Inst)